By Benjamin Chiou
Date: Monday 23 Feb 2026
(Sharecast News) - US pharma group Merck & Co is set to spin off its oncology operations in an effort to keep its wider healthcare businesses immune from a forthcoming patent cliff for its blockbuster Keytruda drug.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 114.18 |
| Change Today | $ -0.02 |
| % Change | -0.02 % |
| 52 Week High | $122.46 |
| 52 Week Low | $73.47 |
| Volume | 36,355,421 |
| Shares Issued | 2,474.63m |
| Market Cap | $282,553m |
| RiskGrade | 92 |
| Strong Buy | 8 |
| Buy | 10 |
| Neutral | 10 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 28 |

| Time | Volume / Share Price |
| 16:04 | 17,214,164 @ $114.18 |
| 16:00 | 300 @ $114.17 |
| 16:00 | 200 @ $114.18 |
| 16:00 | 882 @ $114.18 |
| 16:00 | 5,366 @ $114.18 |
You are here: research